• Login
    View Item 
    •   Home
    • Theses and Dissertations
    • Theses and Dissertations
    • View Item
    •   Home
    • Theses and Dissertations
    • Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of TUScholarShareCommunitiesDateAuthorsTitlesSubjectsGenresThis CollectionDateAuthorsTitlesSubjectsGenres

    My Account

    LoginRegister

    Help

    AboutPeoplePoliciesHelp for DepositorsData DepositFAQs

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    INTRACELLULAR UNBOUND CONCENTRATIONS OF ATORVASTATIN AND BOSENTAN: PREDICTION USING MODELING AND SIMULATION, AND EFFECT OF METABOLISM AND TRANSPORT

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Kulkarni_temple_0225E_12866.pdf
    Size:
    1.917Mb
    Format:
    PDF
    Download
    Genre
    Thesis/Dissertation
    Date
    2017
    Author
    Kulkarni, Priyanka Rajendra
    Advisor
    Nagar, Swati
    Committee member
    Korzekwa, Kenneth
    Wong, Ho-Lun
    Tweedie, Donald J.
    Department
    Pharmaceutical Sciences
    Subject
    Pharmaceutical Sciences
    Permanent link to this record
    http://hdl.handle.net/20.500.12613/1670
    
    Metadata
    Show full item record
    DOI
    http://dx.doi.org/10.34944/dspace/1652
    Abstract
    Accurate prediction of target activity of a drug and rational design of dosing regimen requires knowledge of concentration-time course of the drug at the target. In vitro in vivo correlation (IVIVC) successfully predicts activity and pharmacokinetics of some drugs but is unsuccessful with many others due to poor permeability, transporter activity and use of plasma drug concentrations for determination of PK parameters. According to the free drug hypothesis, at steady state, the unbound drug concentration on either side of a biomembrane is equal. In this case, unbound plasma drug concentration acts as a good surrogate for unbound cell concentrations. However, presence of transporters coupled with poor membrane permeability result in violation of the free drug hypothesis. This results in failure of IVIVC and subsequent discrepancies in the prediction of target activity of pharmacokinetic predictions. Since it is the unbound drug that is capable of exerting the pharmacodynamic effect and available for intracellular metabolizing and transport machinery, knowledge of the unbound concentration inside the cell is very important. Experimental measurement of intracellular unbound concentration is very difficult due to the small size of the cell and complex cellular disposition resulting from activity of metabolizing enzymes, transporters, target binding and organelle binding within the cell. The present study, therefore, aims at predicting the intracellular unbound concentrations using modeling and simulation approach. Liver perfusion experiments were conducted in male Sprague Dawley rats with uptake transporter substrates atorvastatin and bosentan, in presence and absence of inhibitors of active uptake and metabolism, to study tissue distribution of these drugs in presence of uptake transport and metabolism. The outflow perfusate data thus obtained were used as input for the explicit membrane model for liver to predict the unbound intracellular concentrations of atorvastatin and bosentan. Similarly, in vivo pharmacokinetic experiments were also conducted in rats in presence and absence of inhibitors of active uptake and metabolism. The data obtained were used as input for hybrid compartmental models to predict unbound concentrations of these drugs upon intravenous dosing. Modeling exercises were also conducted to study the differential impact of inhibition of active uptake on plasma versus unbound cell concentrations. The effect of uptake transport on the induction potential of bosentan was studied in sandwich cultured rat hepatocytes and in in vivo studies in rats. Inhibition of active uptake in the liver perfusion studies increased the outflow perfusate concentrations, decreased the amount recovered in the bile for atorvastatin and bosentan, and decreased the liver concentrations for atorvastatin. The liver concentrations for bosentan with inhibition of active uptake were not different than the control group. Inhibition of active uptake in the in vivo studies also decreased the systemic clearance of atorvastatin and bosentan. Inhibition of metabolism decreased the systemic clearance of bosentan. It was observed that the perpetrators for metabolism and transport used for this project were not specific for the pathway of interest. Active uptake appeared to be of major significance for disposition of atorvastatin. The model predicted unbound concentrations of atorvastatin at the end of 50 min perfusion were about 7-fold higher in presence of active uptake than in absence of active uptake. On the other hand, inhibition of metabolism resulted in 1.26 fold increase in unbound atorvastatin concentrations inside the cell. Modeling the in vivo data indicated that atorvastatin disposition was not affected until 90% inhibition of active uptake clearance was achieved. However, any further inhibition of active uptake clearance had a largely increased the exposure of this drug. The predicted unbound intracellular bosentan concentrations in presence of active uptake were only marginally higher than in the absence of active uptake, possibly due to inhibition of apical efflux of this drug by the uptake inhibitor, rifampin, used in this study. The modeling exercise showed that in the in vivo studies, BOS disposition was sensitive to intrinsic uptake clearance until 99% inhibition was achieved. However, any further inhibition resulted in minimal change in the exposure of this drug. The differential sensitivity of atorvastatin and bosentan exposure for active uptake clearance was thought to be due to the different diffusional clearance for these drugs. For both atorvastatin and bosentan, simulations indicated that any extent of inhibition of the active uptake clearance did not affect the cell exposure of these drugs. In vitro induction of bosentan could not be characterized in sandwich cultured rat hepatocytes. Bosentan appeared to be a weak inducer of cyp3a mediated metabolism in rats. In summary, the impact of uptake transport and metabolism on the systemic and intracellular disposition of atorvastatin and bosentan was studied. Liver perfusion and in vivo pharmacokinetic studies along with explicit membrane models were successfully used to predict unbound cell concentrations of atorvastatin and bosentan.
    ADA compliance
    For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
    Collections
    Theses and Dissertations

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Temple University Libraries | 1900 N. 13th Street | Philadelphia, PA 19122
    (215) 204-8212 | scholarshare@temple.edu
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.